Introduction
Colorectal cancer (CRC) as one of the most common malignant neoplasm in the world, results from uncontrolled cell growth in the colon, rectum or appendix.
[1] It is obvious that early diagnosis is essential for survival. Fortunately, CRC death rates have reduced in recent years due to the early detection and treatment. However, the prognosis for this cancer remains poor.
[1] Therefore, it is crucial to determine an effective method to detect signs of this disease in its earliest stages.
[1] Many factors have been proposed as independent risk factors helpful in diagnosing, predicting the risk of recurrence and survival rates of cancer. [2] [3] [4] Good biomarkers for early diagnosis of cancer and prognosis are the ones that are present in the early stages of the disease, low or absent in normal subjects or patients with other diseases and easily quantifiable in the circulation. [5] Tumor-associated antigens (TAAs) from cancer cells along with potential tumor biomarkers in human malignancies are appropriate targets for humoral immune response induction.
[6] Autoantibodies (aAbs) are a [7] It is revealed that cancer patients' sera contain antibodies react with TAAs and can be utilized for potential therapeutic purposes, diagnostic and prognostic information of the disease. [8] Serological proteome analysis is a high throughput technique that have been successfully used for proteomics analysis. [9] Antibodies against specific proteins in cell lysates (prepared from tumor tissues or tumor cells in their natural states) can be distinguished by proteomics-based approaches. [10] Endogenous proteins may also earn antigenic properties due to some variation such as changes in expression, posttranslational modifications, conformational changes, and other protein processing events.
[11] Also using western blot technique as a part of proteomics approach can be helpful in identifying aAbs against tumor specific or associated antigens in the first step and design subsequent studies.
